Clinical Trial Update: A Study of BL-B16D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study of BL-B16D1 for head and neck squamous cell carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• BL-B16D1

Snippet

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Conditions: Head and Neck Squamous Cell Carcinomas, Solid Tumor | Phase 1 | Status: RECRUITING